Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2019-002449-39
    Sponsor's Protocol Code Number:42756493BLC2003
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2021-06-17
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2019-002449-39
    A.3Full title of the trial
    A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) and FGFR Mutations or Fusions.
    Studio randomizzato di fase 2 su Erdafitinib verso chemioterapia endovescicale a scelta dello sperimentatore in soggetti affetti da carcinoma uroteliale non muscolo-invasivo ad alto rischio (NMIBC), che presentano mutazioni o fusioni del gene FGFR, trattati con Bacillo di Calmette-Guérin (BCG), e recidivanti.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) and FGFR Mutations or Fusions.
    Studio randomizzato di fase 2 su Erdafitinib verso chemioterapia endovescicale a scelta dello sperimentatore in soggetti affetti da carcinoma uroteliale non muscolo-invasivo ad alto rischio (NMIBC), che presentano mutazioni o fusioni del gene FGFR, trattati con Bacillo di Calmette-Guérin (BCG), e recidivanti.
    A.3.2Name or abbreviated title of the trial where available
    42756493BLC2003
    42756493BLC2003
    A.4.1Sponsor's protocol code number42756493BLC2003
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorJANSSEN CILAG INTERNATIONAL NV
    B.1.3.4CountryBelgium
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportJanssen Research & Development LLC
    B.4.2CountryUnited States
    B.4.1Name of organisation providing supportJanssen Cilag Spa
    B.4.2CountryItaly
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationJanssen-Cilag International NV
    B.5.2Functional name of contact pointClinical Registry Group
    B.5.3 Address:
    B.5.3.1Street AddressArchimedesweg 29
    B.5.3.2Town/ cityLeiden
    B.5.3.3Post code2333 CM
    B.5.3.4CountryNetherlands
    B.5.4Telephone number+31715242166
    B.5.5Fax number+31715242110
    B.5.6E-mailClinicalTrialsEU@its.jnj.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameErdafitinib
    D.3.2Product code [JNJ-42756493]
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNERDAFITINIB
    D.3.9.1CAS number 1346242-81-6
    D.3.9.2Current sponsor codeJNJ-42756493
    D.3.9.3Other descriptive nameD.3.6.2.1 - valore. 8 mg, può essere aumentato fino a 9 mg in base al livello di fosfato a Ciclo1 Day14
    D.3.9.4EV Substance CodeSUB167731
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number3
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameErdafitinib
    D.3.2Product code [JNJ-42756493]
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNERDAFITINIB
    D.3.9.1CAS number 1346242-81-6
    D.3.9.2Current sponsor codeJNJ-42756493
    D.3.9.3Other descriptive nameD.3.6.2.1 - valore. 8 mg, può essere aumentato fino a 9 mg in base al livello di fosfato a Ciclo1 Day14
    D.3.9.4EV Substance CodeSUB167731
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number4
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameErdafitinib
    D.3.2Product code [JNJ-42756493]
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNERDAFITINIB
    D.3.9.1CAS number 1346242-81-6
    D.3.9.2Current sponsor codeJNJ-42756493
    D.3.9.3Other descriptive nameD.3.6.2.1 - valore. 8 mg, può essere aumentato fino a 9 mg in base al livello di fosfato a Ciclo1 Day14
    D.3.9.4EV Substance CodeSUB167731
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 4
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Gemcitabine Accord
    D.2.1.1.2Name of the Marketing Authorisation holderAccord Healthcare B.V.
    D.2.1.2Country which granted the Marketing AuthorisationNetherlands
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameGemcitabine
    D.3.2Product code [Gemcitabine]
    D.3.4Pharmaceutical form Powder for solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravesical use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNGEMCITABINA
    D.3.9.1CAS number 95058-81-4
    D.3.9.2Current sponsor codeGemcitabine
    D.3.9.4EV Substance CodeSUB02324MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number2000
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 5
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Mitomycin Medac
    D.2.1.1.2Name of the Marketing Authorisation holderMedac Gesellschaft für klinische Spezialpräparate mbH
    D.2.1.2Country which granted the Marketing AuthorisationGermany
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameMitomycin/ Hyperthermic Mitomycin
    D.3.2Product code [Mitomycin]
    D.3.4Pharmaceutical form Powder for solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravesical use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNMITOMICINA
    D.3.9.1CAS number 50-07-7
    D.3.9.2Current sponsor codeMitomycin
    D.3.9.4EV Substance CodeSUB09006MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 6
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Mitomycin Accord Healthcare, Inc
    D.2.1.1.2Name of the Marketing Authorisation holderAccord Healthcare, Inc
    D.2.1.2Country which granted the Marketing AuthorisationUnited States
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameMitomycin/ Hyperthermic Mitomycin
    D.3.2Product code [Mitomycin]
    D.3.4Pharmaceutical form Powder for solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravesical use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNMITOMICINA
    D.3.9.1CAS number 50-07-7
    D.3.9.2Current sponsor codeMitomycin
    D.3.9.4EV Substance CodeSUB09006MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number40
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 7
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Gemcitabine Accord
    D.2.1.1.2Name of the Marketing Authorisation holderAccord Healthcare Limited
    D.2.1.2Country which granted the Marketing AuthorisationUnited Kingdom
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameGemcitabine
    D.3.2Product code [Gemcitabine]
    D.3.4Pharmaceutical form Powder for solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravesical use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNGEMCITABINA
    D.3.9.1CAS number 95058-81-4
    D.3.9.2Current sponsor codeGemcitabine
    D.3.9.4EV Substance CodeSUB02324MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number2000
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Cohort 1 and 2: High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) with FGFR Mutations or Fusions
    Cohort 3 Intermediate Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) with FGFR Mutations or Fusions
    Coorte 1 e 2: carcinoma uroteliale non muscolo-invasivo ad alto rischio (NMIBC) mutazioni o fusioni del gene FGFR
    Coorte 3: carcinoma uroteliale non muscolo-invasivo a rischio intermedio (NMIBC) mutazioni o fusioni del gene FGFR
    E.1.1.1Medical condition in easily understood language
    Bladder Cancer
    carcinoma uroteliale
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level SOC
    E.1.2Classification code 10029104
    E.1.2Term Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Cohort 1 only:
    -To evaluate RFS in subjects treated with erdafitinib vs Investigator’s Choice, for subjects with high-risk NMIBC who harbor FGFR mutations or fusions, and who recurred after BCG therapy
    Solo Coorte 1:
    - Valutare la sopravvivenza libera da recidiva (RFS) nei soggetti trattati con erdafitinib vs la scelta dello sperimentatore, per soggetti con NMIBC ad alto rischio che presentano mutazioni o fusioni di FGFR e con recidiva in seguito a terapia con BCG.
    E.2.2Secondary objectives of the trial
    Cohort 1 only:
    -To evaluate other measures of efficacy

    All cohorts:
    -To evaluate erdafitinib PK
    -To evaluate safety and tolerability of erdafitinib
    -To evaluate HRQoL
    -To evaluate the potential DDI of repeated dosing of erdafitinib on the single-dose pharmacokinetics of other drugs affected by CYP3A metabolism and OCT2 transport in a substudy performed at select study sites. In addition, local erdafitinib concentration in the bladder may be determined for a subset of subjects from study sites participating in the DDI substudy as an exploratory endpoint.
    Solo Coorte 1:
    - Valutare altre misure di’efficacia.

    Tutte le coorti:
    - Valutare la farmacocinetica di erdafitinib
    - Valutare la sicurezza e la tollerabilità di erdafitinib
    - Valutare la qualità della vita correlata alla salute (HRQoL)
    - Valutare la potenziale interazione farmacologica (DDI) di ripetute somministrazioni di erdafitinib e la farmacocinetica di una dose singola di altri farmaci soggetti al metabolismo del CYP3A e al trasporto mediato dagli OCT2, nell’ambito di un sottostudio svolto presso selezionati centri di sperimentazione. Inoltre, la concentrazione locale di erdafitinib nella vescica può essere selezionata come endpoint esploratorio per un sottogruppo di soggetti dei centri di sperimentazione che partecipano al sottostudio DDI.
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives

    Other types of substudies
    Specify title, date and version of each substudy with relative objectives: Protocol title: Drug-drug interaction substudy to assess the effect of repeated doses of erdafitinib on the single-dose pharmacokinetics of midazolam and metformin in FGFR-positive subjects with high-risk nonmuscle-invasive bladder cancer at selected sites.
    Protocol date: 24 September 2019
    Objectives:
    The objective of this DDI substudy is to evaluate the effects of repeated dosing of erdafitinib on the single-dose pharmacokinetics (PK) of midazolam and metformin in FGFR-positive subjects with high-risk NMIBC. In addition, local erdafitinib concentration in the bladder may be determined.
    This substudy is only planned in following countries: Belgium, France, Spain and USA.

    Altre tipologie di sottostudi
    specificare il titolo, la data e la versione di ogni sottostudio con i relativi obiettivi: Titolo del protocollo: sottostudio di interazione farmaco-farmaco per valutare l'effetto di dosi ripetute di erdafitinib sulla farmacocinetica monodose di midazolam e metformina in soggetti positivi alla FGFR con carcinoma uroteliale non muscolo-invasivo ad alto rischio in siti selezionati.
    Data del protocollo: 24 settembre 2019
    obiettivi:
    L'obiettivo di questo sottostudio DDI è di valutare gli effetti della somministrazione ripetuta di erdafitinib sulla farmacocinetica (PK) a dose singola di midazolam e metformina in soggetti positivi alla FGFR con NMIBC ad alto rischio. Inoltre, può essere determinata la concentrazione locale di erdafitinib nella vescica.
    Questo sottostudio è previsto solo nei seguenti Paesi: Belgio, Francia, Spagna e Stati Uniti.
    E.3Principal inclusion criteria
    1. >=18 yrs of age (or the legal age of consent in the jurisdiction in which the study is taking place).
    2. Histologically confirmed, recurrent, non-muscle-invasive urothelial carcinoma of the bladder.
    a. Histopathology: any urothelial cell carcinoma (UCC) variant (ie, UCC with squamous and/or glandular differentiation, micropapillary, nested, plasmacytoid, neuroendocrine, sarcomatoid) are allowed. Presence of any lymphovascular invasion (LVI) will be considered as evidence of high risk.
    b.Papillary disease (Cohort 1) must be high-risk disease, defined high-grade disease Ta/T1 lesion. Additionally, subjects must have all visible tumor resected completely prior to randomization and documented at baseline cystoscopy. Negative cytology for high-grade urothelial carcinoma is required before randomization.
    c.CIS (Cohort 2) is not expected to be completely excised, but concurrent papillary disease must be completely excised before enrollment and documented at baseline cystoscopy. Urine cytology is not expected to be negative for malignant cells.
    d.Marker Lesion (Cohort 3) must have recurrent intermediate-risk disease with all previous tumors being low grade (G1-G2), Ta or T1, and no previous CIS. Additionally, subjects must have a risk of progression less than 5% in the next 2 yrs and a risk of recurrence greater than 50%, calculated using the EORTC risk calculator. All tumors must be removed except for a single untouched 5 to 10 mm lesion (Marker Lesion).
    3. Criterion modified per Amendment 2
    3.1 At least 1 of the following tumor FGFR mutations or fusions as determined by local or central testing at the time of recurrence after BCG therapy: see table in protocol
    4. Criterion modified per Am. 1.
    4.1.
    4a. BCG-unresponsive.
    BCG-unresponsive subjects must meet at least one of the following:
    i. Persistent or recurrent CIS alone or with recurrent Ta/T1 (noninvasive papillary disease/tumor invades the subepithelial connective tissue) disease within 12m of completion of adequate BCG therapy (Cohort 2 only)
    ii. Recurrent high-grade Ta/T1 disease within 6m of completion of adequate BCG therapy
    iii. T1 high-grade at the first disease assessment following an induction BCG course
    Adequate BCG (Minimum Treatment Requirements)
    1) At least 5 of 6 full doses of an initial induction course plus at least 1 maintenance (2 of 3 weekly full doses) in a 6m period
    OR
    2) At least 5 of 6 full doses of an initial induction course plus at least 2 of 6 full doses of a second induction course.
    4b BCG Experienced.
    BCG experienced subjects must meet the following:
    i. Recurrent high-grade Ta/T1 disease within 12m of completion of BCG therapy
    Prior BCG (Minimum Treatment Requirements)
    1) At least 5 of 6 full doses of an initial induction course
    2) OR
    3) At least 5 of 6 full doses of an initial induction course plus at least 1 maintenance (2 of 3 weekly doses) in a 6m period. One-half dose or one-third dose is allowed during maintenance
    5. Refuses or is not eligible for cystectomy (Cohort 1 and Cohort 2 only)
    6. Eastern Cooperative Oncology Group (ECOG) performance status Grade 0 or 1
    7. Criterion modified per Amendment 2
    7.1 Adequate bone marrow, liver, and renal function:
    a. Bone marrow function (without the support of cytokines or erythropoiesis-stimulating agent in preceding 2wks):
    i. Absolute neutrophil count (ANC) >=1,000/mm3
    ii. Platelet count >=75,000/mm3
    iii.Hemoglobin >=8.0 g/dL
    b.Liver function:
    i.Total bilirubin <=1.5 x institutional ULN OR direct bilirubin <=ULN for subjects with total bilirubin levels >1.5xULN
    ii.Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <=2.5x institutional ULN
    c.Renal function:
    Creatinine clearance >30 mL/min calculated using the Cockcroft-Gault formula.
    For the DDI substudy, creatinine clearance >=60 mL/min
    d. Phosphate: <ULN within 14 dys before the first dose of study drug on C1D1 (medical management allowed)
    10. Criterion modified per Amendment 2
    10.1
    For All criteria see protocol
    Età =18a (o maggiore età legale)
    2.Carcinoma vescicale uroteliale non muscolo invasivo confermato istologicamente e recidivo.
    a.Istopatologia: è ammessa ogni variante del carcinoma delle cellule uroteliali (UCC) (UCC con differenziazione squamosa e/o ghiandolare, UCC micropapillare, nested, plasmacitoide, neuroendocrino o sarcomatoide). La presenza di invasione linfovascolare (LVI) sarà considerata come evidenza di alto rischio
    b.La malattia papillare (Coorte 1) deve essere ad alto rischio, definita come lesione Ta/T1 di alto grado. I soggetti devono inoltre essere sottoposti a resezione completa di tutti i tumori visibili prima della randomizzazione, con documentata cistoscopia al basale. Prima della randomizzazione l’esame citologico deve rilevare negatività al carcinoma uroteliale di alto grado
    c.Mentre non si prevede una resezione totale del CIS (Coorte 2), è prevista, prima dell’arruolamento, completa resezione di malattia papillare concomitante, documentata al momento della cistoscopia al basale. Per l’esame citologico delle urine non è prevista negatività alle cellule maligne
    d.La lesione marker (Coorte 3) deve essere a rischio intermedio di recidiva, qualsiasi tumore pregresso deve essere di basso grado (G1-G2), Ta o T1 e non sono ammessi precedenti CIS. I soggetti devono presentare rischio di progressione inferiore al 5% nei 2aa successivi e rischio di recidiva >al 50% (calcolatore di rischio EORTC). Tutti i tumori devono essere rimossi tranne singola lesione di 5-10 mm (lesione marker)
    3.Mod eme2
    3.1 Almeno 1 delle mutazioni o fusioni di FGFR, secondo i risultati delle analisi centrali o locali, al momento della recidiva in seguito a terapia con BCG: vedere tabella nel protocollo
    4.Mod eme2
    4.14a Soggetti con mancata risposta a BCG
    I soggetti che non hanno risposto al BCG devono soddisfare almeno uno dei seguenti requisiti:
    i.CIS persistente o recidivo da solo o con malattia Ta/T1 recidiva (la malattia papillare non invasiva/il tumore invade il tessuto connettivo sottoepiteliale) entro 12 mesi (m) dal completamento di adeguata terapia con BCG (solo Coorte 2)
    ii.Malattia di alto grado Ta/T1 recidiva entro 6m dal completamento di adeguata terapia con BCG
    iii.T1 di alto grado a prima valutazione di malattia in seguito a trattamento di induzione con BCG
    Adeguata terapia con BCG (requisiti minimi di trattamento)
    1.Almeno 5 su 6 dosi complete di trattamento di induzione più almeno 1 trattamento di mantenimento (2 di 3 dosi complete setti) in 6m.
    O
    2.Almeno 5 su 6 dosi complete di un trattamento di induzione più almeno 2 delle 6 dosi complete di un secondo trattamento di induzione.
    4b Soggetti precedentemente trattati con BCG
    I soggetti già trattati con BCG devono soddisfare i seguenti requisiti:
    i.Malattia di alto grado Ta/T1 recidiva entro 12m dal completamento della terapia con BCG (come definito di seguito)
    j.Precedente terapia con BCG (requisiti minimi di trattamento)
    1)Almeno 5 su 6 dosi complete di un trattamento di induzione
    O
    2)Almeno 5 su 6 dosi complete di un trattamento di induzione più almeno 1 trattamento di mantenimento (2 su 3dosisett) in 6m. Durante il mantenimento sono ammessi metà o un terzo di dose.
    5.Rifiuta o non idoneo alla cistectomia (solo Coorte 1 e Coorte 2)
    6.Punteggio di stato di prestazione ECOG pari a 0 o 1
    7.Mod eme2
    7.1Adeguata funzione del midollo osseo, epatica e renale:
    a.Funzione del midollo osseo (senza supporto di citochine o agente stimolante eritropoiesi nelle 2 sett. precedenti):
    i.ANC >=1.000/mm3
    ii.conta piastrinica >=75.000/mm3
    iii.Emoglobina >=8,0 g/dL
    b.Funzione epatica:
    i.bilirubina totale <=1,5 x ULN O bilirubina dir. <=ULN in soggetti con livelli totali di bilirubina >1,5 x ULN
    ii.ALT e AST <=2,5 x ULN
    c.Funzione renale:
    Clearance creatinina >30 mL/min calcolata con formula Cockcroft-Gault
    d.Fosfato: <ULN entro i 14gg precedenti assunzione 1a dose di farmaco in studio alC1D1
    E.4Principal exclusion criteria
    1. Histologically confirmed, muscle-invasive (T2 or higher stage) urothelial carcinoma of the bladder
    2. Histopathology demonstrating any small cell component, pure adenocarcinoma, pure squamous cell carcinoma, or pure squamous CIS of the bladder
    3. Prior treatment with an FGFR inhibitor
    4. Active malignancies (ie, progressing or requiring treatment change in the last 24 months) other than the disease being treated under study. The only allowed exceptions are:
    a. skin cancer treated within the last 24 months that is considered completely cured
    b. adequately treated lobular carcinoma in situ (LCIS) and ductal CIS
    c. history of localized breast cancer and receiving antihormonal agents, or history of localized prostate cancer (N0M0) and receiving androgen deprivation therapy
    5. Current central serous retinopathy or retinal pigment epithelial detachment of any grade
    6. History of uncontrolled cardiovascular disease including:
    a. any of the following in the preceding 3 months: unstable angina, myocardial infarction, ventricular fibrillation, Torsades de Pointes, cardiac arrest, or known congestive New York Heart Association Class III-IV heart failure, cerebrovascular accident, or transient ischemic attack.
    b. QTc prolongation as confirmed by ECG assessment at screening (Fridericia; QTc >480 milliseconds).
    c. Pulmonary embolism or other venous thromboembolism within the preceding 2 months.
    7. Criterion modified per Amendment 1.
    7.1. Known human immunodeficiency virus (HIV) infection, unless the subject has been on a stable anti-retroviral therapy regimen for the last 6 months or more and has had no opportunistic infections and a CD4 count >350 in the last 6 months.
    8. Criterion modified per Amendment 1.
    8.1. Evidence of active hepatitis B or C infection (for example, subjects with history of hepatitis C infection but normal hepatitis C virus polymerase chain reaction test and subjects with hepatitis B with positive HBsAg antibody are allowed).
    9. Not recovered from toxicity of prior anticancer therapy (except toxicities which are not clinically significant such as alopecia, skin discoloration, neuropathy, hearing loss)
    10. Impaired wound healing capacity defined as skin/decubitus ulcers, chronic leg ulcers, known gastric ulcers, or unhealed incisions
    11. Major surgery within 4 weeks before Cycle 1 Day 1 (TURBT is not considered major surgery)
    12.Criterion modified per Amendment 2
    12.1 Severe hypocalcemia (corrected serum calcium of <7 mg/dl), acute and unhealed bone fractures, known underlying bone disease, or at an increased risk of bone fracture. In addition, any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subjects (eg, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments. Examples include ongoing active infection requiring systemic therapy and uncontrolled ongoing medical conditions.
    13. Use of strong CYP3A4 inhibitors or inducers or moderate CYP3A4 inducers(Section 10.9) within 14 days or 5 half-lives (whichever is longer) before the first dose of study drug
    14. As determined by the investigator, contraindications to the use of gemcitabine or MMC/hyperthermic MMC (Cohort 1) per local prescribing information
    1.Carcinoma vescicale uroteliale muscolo invasivo (di stadio T2 o superiore) confermato istologicamente
    2.Piccoli componenti cellulari, adenocarcinoma puro, carcinoma squamocellulare puro o CIS squamocellulare puro della vescica rilevati dall’esame istopatologico.
    3.Precedente trattamento con un inibitore di FGFR
    4.Neoplasie maligne attive (ossia in progressione oppure che abbiano necessitato di una modifica del trattamento nei 24 mesi precedenti) diverse dalla malattia trattata nello studio. Le uniche eccezioni consentite sono:
    a. cancro della pelle trattato entro i 24 mesi precedenti e considerato completamente curato
    b. carcinoma lobulare in situ (LCIS) e CIS duttale adeguatamente trattati
    c. cancro al seno localizzato in anamnesi e terapia in corso con agenti antiormonali, oppure cancro localizzato della prostata (N0M0) in anamnesi e terapia di deprivazione androgenica in corso
    5.Attuale retinopatia sierosa centrale o distacco dell'epitelio pigmentato retinico di qualsiasi grado
    6.Anamnesi di patologia cardiovascolare non controllata tra cui:
    a.Una qualsiasi delle seguenti patologie nei 3 mesi precedenti: angina instabile, infarto del miocardico, fibrillazione ventricolare, torsioni di punta, arresto cardiaco, oppure nota insufficienza cardiaca congestizia di classe III-IV secondo la scala della New York Heart Association (sezione 10.7), accidente cerebrovascolare o attacco ischemico transitorio.
    b.Prolungamento dell’intervallo QTc confermato con valutazione ECG allo screening (Fridericia; QTc >480 millisecondi).
    c.Embolia polmonare o altra tromboembolia venosa entro i 2 mesi precedenti.
    7.Critero Modificato per Emendamento 1
    7.1 Nota infezione da virus dell’immunodeficienza umana (HIV), a meno che il soggetto non assuma un regime terapeutico antiretrovirale stabile da almeno 6 mesi e che sia stato esente da infezioni opportunistiche e abbia una conta CD4 >350 nei 6 mesi precedenti .
    8.Criterio Modificato per Emendamento 1
    8.1 Evidenza di nfezione da epatite B o C attiva (ad esempio, soggetti con storia di infezione da epatite C, ma con epatite C PCR test normale e soggetti con epatite B e positivi agli anticorpi HBsAg sono ammessi).
    9.Mancato recupero dopo una tossicità causata da una precedente terapia antitumorale (ad eccezione delle tossicità non clinicamente significative, come alopecia, scolorimento della pelle, neuropatia, calo dell’udito).
    10.Ridotta capacità di guarigione delle ferite definita come ulcere cutanee/da decubito, ulcere croniche degli arti inferiori, ulcere gastriche note o incisioni non guarite.
    11.Intervento chirurgico importante entro le 4 settimane precedenti il Ciclo 1 Giorno 1 (la TURBT non è considerata un intervento chirurgico importante).
    12.Mod per Eme 2
    12.1 Ipocalcemia grave (calcio sierico corretto <7 mg / dl), fratture ossee acute e non cicatrizzate, importanti patologie ossee note o con aumentato rischio di fratture ossee.In aggiunta,e, presenza di qualsiasi condizione per cui, secondo il giudizio dello sperimentatore, la partecipazione non sarebbe nel miglior interesse del soggetto (ad es. ne comprometterebbe il benessere) o potrebbe impedire, limitare o confondere le valutazioni specificate dal protocollo. A titolo esemplificativi si citano infezioni attive in corso che richiedono terapia sistemica e condizioni mediche non controllate in corso.
    13.Uso di potenti inibitori del CYP3A4 o induttori oppure di induttori moderati del CYP3A4 (sezione 10.9) entro i 14 giorni precedenti o le 5 emivite precedenti l’assunzione della prima dose di farmaco dello studio (a seconda del periodo di più lunga durata)
    14. Controindicazioni, all'uso di gemcitabina o MMC / MMC ipertermica (Coorte 1) secondo il giudizio dello sperimentatore o le indicazioni di prescrizione locali.
    E.5 End points
    E.5.1Primary end point(s)
    Recurrence-free survival (RFS)
    Sopravvivenza libera da recidiva
    E.5.1.1Timepoint(s) of evaluation of this end point
    At study analysis
    Analisi di studio
    E.5.2Secondary end point(s)
    1. Time to progression
    2. Time to disease worsening
    3. Disease-specific survival (invasive bladder cancer)
    4. OS
    5. RFS rate at 6, 12, and 24 months
    6. RFS2
    7. RFS by central histopathologic review
    1. Tempo di progressione
    2. Tempo di peggioramento della malattia
    3. Sopravvivenza specifica per malattia (carcinoma vescicale invasivo)
    4. OS
    5. Tasso di RFS a 6, 12 e 24 mesi
    6. RFS2
    7. RFS mediante revisione istopatologica centrale
    E.5.2.1Timepoint(s) of evaluation of this end point
    1. Throughout the study
    2. Throughout the study
    3. Throughout the study
    4. Throughout the study
    5. At 6, 12 and 14 months
    6. Throughout the study
    7. Throughout the study
    1. Durante lo studio
    2. Durante lo studio
    3. Durante lo studio
    4. Durante lo studio
    5. A 6, 12 e 14 mesi
    6. Durante tutto lo studio
    7. Durante lo studio
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Biomarkers
    Biomarkers
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned9
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA56
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Brazil
    China
    Japan
    Korea, Republic of
    Taiwan
    United States
    Belgium
    France
    Germany
    Italy
    Poland
    Spain
    United Kingdom
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The study is considered completed with the last follow-up survival assessment for the last subject participating in the study, or 4 years after the last subject is enrolled.
    Lo studio è considerato completato con l'ultima valutazione di sopravvivenza di follow-up per l'ultimo soggetto che ha partecipato allo studio, o 4 anni dopo l'arruolamento dell'ultimo soggetto.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years6
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years5
    E.8.9.2In all countries concerned by the trial months7
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 28
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 252
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception Yes
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state27
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 156
    F.4.2.2In the whole clinical trial 280
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    The sponsor will ensure that subjects benefiting from treatment with erdafitinib continue to receive treatment after the end of the study. Subsequent anticancer therapy is left to the investigator's discretion.
    Lo sponsor garantirà che i soggetti che beneficiano del trattamento con erdafitinib continuino a ricevere il trattamento dopo la fine dello studio. La terapia antitumorale successiva è lasciata alla discrezione dello sperimentatore.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2020-03-10
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2020-02-05
    P. End of Trial
    P.End of Trial StatusCompleted
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 14:19:15 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA